Citalopram (CelexaŽ) | Print |  Email

Trial status: Enrolling at University of Iowa.

Trial name: CIT-HD

FDA phase: Phase II

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Trial design:  A randomized, double-blind, placebo-controlled, pilot clinical trial in 20 people with HD between the ages of 18 and 60, to consider the efficacy of citalopram.  The trial lasts about 21 weeks and requires eight outpatient visits and two telephone visits.  Participants will be offered travel reimbursement and some compensation for participation.

Outcome measures: Comparison of executive function before and after treatment.  Other assessments include cognitive and functional measures and brain imaging.

Location: University of Iowa

Contact information: Please contact William H. Adams, study coordinator, by phone at 1-319-353-4411, or by e-mail at This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

 
< Prev   Next >

To comment on this article or contact HDDW for any other reason, please email us.

© 2007 HDDW. All Rights Reserved.